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Abstract
Background: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune
responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to
evaluate comprehensively the immunogenicity of the vaccine at peak response, the factors affecting it, and the
antibodies associated with protection against clinical malaria in young African children participating in the multicenter
phase 3 trial for licensure.
Methods: We measured total IgM, IgG, and IgG1–4 subclass antibodies to three constructs of the Plasmodium falciparum
circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg) that are part of the RTS,S vaccine, by quantitative
suspension array technology. Plasma and serum samples were analyzed in 195 infants and children from two sites in
Ghana (Kintampo) and Mozambique (Manhiça) with different transmission intensities using a case-control study design.
We applied regression models and machine learning techniques to analyze immunogenicity, correlates of protection, and
factors affecting them.
Results: RTS,S/AS01E induced IgM and IgG, predominantly IgG1 and IgG3, but also IgG2 and IgG4, subclass responses.
Age, site, previous malaria episodes, and baseline characteristics including antibodies to CSP and other antigens reflecting
malaria exposure and maternal IgGs, nutritional status, and hemoglobin concentration, significantly affected vaccine
immunogenicity. We identified distinct signatures of malaria protection and risk in RTS,S/AS01E but not in comparator
vaccinees. IgG2 and IgG4 responses to RTS,S antigens post-vaccination, and anti-CSP and anti-P. falciparum antibody levels
pre-vaccination, were associated with malaria risk over 1-year follow-up. In contrast, antibody responses to HBsAg (all
isotypes, subclasses, and timepoints) and post-vaccination IgG1 and IgG3 to CSP C-terminus and NANP were associated
with protection. Age and site affected the relative contribution of responses in the correlates identified.
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Conclusions: Cytophilic IgG responses to the C-terminal and NANP repeat regions of CSP and anti-HBsAg antibodies
induced by RTS,S/AS01E vaccination were associated with malaria protection. In contrast, higher malaria exposure at
baseline and non-cytophilic IgG responses to CSP were associated with disease risk. Data provide new correlates of
vaccine success and failure in African children and reveal key insights into the mode of action that can guide
development of more efficacious next-generation vaccines.
Keywords: Malaria, Vaccine, Antibody, RTS,S, Plasmodium falciparum, Immunogenicity, Correlate protection, African
children, Hepatitis B
Background
Malaria was estimated to cause 445,000 deaths globally in
2016, mostly attributable to Plasmodium falciparum in
African children [1]. A reduction in malaria-associated
deaths and morbidity has been attained in the last years by
combining malaria control interventions, such as vector-
targeted measures including distribution of long-lasting
insecticide-treated bednets and indoor residual spraying, as
well as mass drug administration [2]. However, emerging
mosquito resistance to insecticides [3], parasite resistance
to drugs [4–7], and non-sustained surveillance strategies [8]
can jeopardize malaria elimination strategies. Furthermore,
there is a potential for a rebound of malaria illness if im-
munity is lost as a result of sustained elimination cam-
paigns, in case P. falciparum transmission is later
reintroduced [9]. In this scenario, an effective malaria vac-
cine remains an essential tool to reduce and sustain malaria
burden at low levels and facilitate elimination [10].
RTS,S/AS01E (Mosquirix™) has consistently provided
partial protection against malaria in African children, as
demonstrated in phase 3 clinical trial [11–15]. RTS,S/
AS01E is based on virus-like particles with the hepatitis
B surface antigen (HBsAg) and a fragment of the P.
falciparum circumsporozoite protein (CSP), which com-
prises the central repeat region (NANP)n and the C-
terminus (C-term) [16], formulated with GlaxoSmithK-
line’s proprietary adjuvant AS01. RTS,S/AS01E generates
high IgG titers to the CSP NANP immunodominant B
cell epitope that remains above naturally acquired titers
for years [17]. However, such antibodies have not con-
sistently correlated with protection across all ages and
malaria endpoints [14, 18]. Since only total IgG re-
sponses to NANP have been measured in field trials thus
far, it is possible that (i) other CSP antigenic epitopes are
targets of vaccine-induced protective immunity and (ii)
the isotype/subclass balance, important for effector func-
tion of antibodies, is more relevant in protection against
malaria than the magnitude of the IgG response. Binding
kinetics of anti-NANP antibodies has been analyzed in
pilot experiments and showed no strong association with
protection in African children, although longitudinal
analyses indicated an effect of previous exposure to vac-
cine or natural infection [19, 20] that can be mimicked
by fractional last doses [21]. This shows that it is crucial
to understand how RTS,S immunogenicity and vaccine
efficacy are affected by baseline factors like age at first
vaccination, sex, maternal antibodies, and malaria trans-
mission intensity (MTI) [22]. Efforts to improve RTS,S
efficacy to rationally develop and deploy second-gener-
ation vaccines should rely on a better understanding of
its mode of action, currently unknown, to unravel why
RTS,S does not prevent a higher proportion of malaria
episodes in African children and what are the factors af-
fecting this.
In this study, we set out to characterize in detail the
immunogenicity of the RTS,S/AS01E vaccine in the
African pediatric multicenter phase 3 clinical trial and
assess the association between the fine epitope specifi-
city and isotype/subclass of the antibody response and
protection against clinical malaria. We measured total
IgG and, for the first time, IgM as well as IgG1, IgG2,
IgG3, and IgG4 responses to the HBsAg and to three
CSP constructs: a full-length (FL) and two truncated
proteins, one with the central NANP16 repeat region
and the other with the C-term region [16]. In addition,
we investigated the effect of baseline variables including
age, malaria exposure, maternal antibodies, sex, and nu-
tritional status on immunogenicity and protection. By
applying regression models and machine learning tech-
niques, we identified novel antibody signatures at base-
line and induced by RTS,S/AS01E vaccination that
correlated with protection and risk from clinical malaria,
defined their antigen targets and Ig isotypes/subclasses,
and assessed their determinants.
Methods
Design
This study was carried out in two of the seven sites
included in the multicenter immunology study MAL067,
ancillary to the phase 3 randomized clinical trial MAL055
(NCT00866619)—Kintampo in Ghana (representative of
moderate-high MTI) and Manhiça in Mozambique (repre-
sentative of low MTI) [18], to be able to assess the effect
of MTI on vaccine responses. These two sites were
prioritized due to higher availability of sufficient numbers
and volumes of samples from both study visits and age
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cohorts. Subjects were followed up by passive case detec-
tion (PCD) starting 14 days after sample collection at
month (M) 3, approximately 44 days after the third dose
(M2), for the subsequent 12 months, when they were
censored.
Children age 5–17 months and infants age 6–12 weeks
with ≥ 150 μL plasma/serum samples available at M0
(baseline) and M3 were selected. We included 129 RTS,S/
AS01E-vaccinated and 66 comparator-vaccinated children
and infants from both sites (Fig. 1, Additional file 1: Table
S1). For the correlates of malaria disease protection and
risk analysis, 78 children and infants were randomly
selected from Kintampo, 117 participants were selected
from Manhiça according to a prior case-control study of
cellular markers [23], and all were analyzed in a case-con-
trol design.
Antibody assays
Quantitative suspension array technology (qSAT) [24,
25] was used to measure antibody responses to three
CSP constructs (FL, NANP repeat, and C-term [residues
274 to 387: KNNQG...SSIGL] recombinant proteins
from WRAIR) and HBsAg (Abcam). The qSAT assays
applied the xMAP™ technology (Luminex Corp., TX)
and were previously standardized and optimized to con-
trol for sources of variability [26, 27]. The multiplex
antigen panel also included 32 P. falciparum proteins
[26, 27] analyzed as markers of malaria exposure and
maternally transferred antibodies (see below). Briefly,
antigen-coupled multiplex beads were mixed with 50 μL
of test sample, negative or positive control [28, 29] at
multiple dilutions (see Additional file 1: Supplementary
methods). After incubation and washing, biotinylated
secondary antibodies were added. Following streptavidin-
R-phycoerythrin incubations, samples were acquired with
a Luminex 100/200 analyzer and antibody levels measured
as median fluorescence intensity (MFI). Data pre-processing
is detailed in Additional file 1: Supplementary methods.
Statistical analysis
RTS,S/AS01E immunogenicity was evaluated for all anti-
gens/Ig using basic descriptive methods (see Additional file 1:
Supplementary methods) and longitudinal linear mixed ef-
fects models [30] including vaccination, visit (M0, M3) and
the interaction between them, and adjusting by site. The ef-
fect of the vaccine on Ig responses at M3, and on change on
Ig levels from M0 to M3, was assessed through tests of the
corresponding fixed effects. All models included a random
intercept for the individual and a random slope for changes
over time among predictors (see Additional file 1: Supple-
mentary methods). To evaluate more thoroughly the impact
of age on post-vaccination levels and association between
pre- and post-vaccination in RTS,S vaccinees, mixed effects
models adjusted by site were also estimated across age co-
horts (children and infants).
To understand the effect of the remaining study covari-
ates on M3 Ig levels to all antigens, we fitted first univariate
and next multivariable linear regression models (coefficient,
95% confidence intervals (CI), adjusted p values) including
only RTS,S vaccinees, with the following predictors: sex,
malaria transmission season at M3, having clinical malaria
episodes between M0 and M3, and baseline variables like
Fig. 1 Flowchart of the study population. Inf. infants, Chil children, EVENTS events of clinical malaria
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age (in weeks), antibody levels, hemoglobin (Hb) concentra-
tions, weight-for-age Z score (WAZ), and height-for-age Z
score (HAZ). For comparison purposes, models were also
fitted at pre-vaccination and on comparator vaccinees at
M3. Malaria transmission season was defined as high
between April–October for Kintampo and November–
April for Manhiça; the remaining months were defined as
low transmission. The effect of baseline antibody levels was
evaluated in three different ways. First, using the same anti-
gen/Ig as the outcome variable at M3. Second, a P.
falciparum exposure index was defined as follows [27, 31].
Upon examination of antibody responses to the 32 antigen
panel [26, 27], we selected 28 markers in which IgM
responses were M3 >M0 and thus acquired with age (e.g.,
children > infants) and exposure (e.g., Kintampo > Man-
hiça). Principal component analysis (PCA) of IgM re-
sponses to these antigens was performed to construct the
corresponding variables, and the first component (PC1)
that explained 63% of the variability was selected. Third, a
P. falciparum maternal antibody index was defined in sub-
jects < 10 months of age [27, 31]. For this, 17 antigens in-
cluding two VAR2CSA pregnancy-specific antigen
constructs were selected which IgG responses were M0 >
M3 and thus declined with age (e.g., infants > children) and
were higher in infants from the high MTI site (e.g., Kin-
tampo > Manhiça). The construction of the maternal score
was done in the same way as the exposure score. We se-
lected the first component that explained 54% of the vari-
ability. Linearity of the associations with continuous
covariates was evaluated through penalized splines in gen-
eralized additive models (GAM); variables were modeled as
linear. A stepwise algorithm was used in multivariable
models.
Analysis of correlates of protection was based on the
case-control design. The outcome was clinical malaria
detected by PCD defined by fever > 37.5 °C with any
parasitemia in the 12 months after the start of follow-up
(M3 plus 14 days). Logistic regression models (odds ratio
(OR), 95% CI, adjusted p values) were fitted first univari-
ate and next multivariable to obtain the effect of differ-
ent predictors in the odds of having malaria. Main
predictors included levels (log10MFI) of antibodies at
M3, increment of antibody levels between M0 and M3,
and ratios (IgG1 + IgG2)/(IgG2 + IgG4) at M3, in RTS,S
vaccinees (comparators modeled separately for compari-
son purposes). The impact of the other covariates (same
as above) on the association between antibody responses
and clinical malaria risk/protection was also assessed.
The linearity of the log10-transformed antibody levels
was evaluated when the outcome was case-control. Uni-
variate models were adjusted by site.
Next, multivariable models were obtained in RTS,S-vac-
cinated subjects through the stepwise algorithm, R pack-
age MASS, and function stepAIC. Both backwards and
forward methods were combined to obtain the model with
the minimum Akaike information criterion (AIC). All
potential single variables were proposed in the first step of
the model, not only the significant ones. For the assess-
ment of the maternal index, only subjects < 10 months
were taken into account. Correction for multiple testing
was done by Holm [32] when analyzing IgG and IgM
(with the following predictors: M3 antibody levels and
M0–M3 change in antibodies) and IgG subclass ratios.
Benjamini-Hochberg [33] was used when IgG1–4 subclass
levels were the predictors. Holm was used to control for
family wise error when there were few tests, whereas
Benjamini-Hochberg was used to control for the false dis-
covery rate when there were more tests (e.g., IgG1–4).
HBsAg was analyzed separately from CSP constructs.
Finally, to identify the most relevant antibody variables
associated with clinical malaria in multi-marker analysis,
three machine learning algorithms were computed: (i)
elastic net, which is a shrinkage regression that simultan-
eously does automatic variable selection and continuous
shrinkage and can select groups of correlated variables; (ii)
recursive feature elimination algorithm using support vec-
tor machines (SVM) [34] with linear kernel, which recur-
sively removes features of low importance (computed
using the weights of the linear SVM); and (iii) random for-
est, which constructs a multitude of uncorrelated decision
trees and defines the importance of each variable by apply-
ing the permutation of the variable’s values approach [35].
The optimal tuning parameter values for each machine
learning method, i.e., α and λ penalty parameters of elastic
net, cost parameter of linear SVM, and number of trees
and number of variables to be included in each iteration
of random forest, were computed using a 5-fold cross-val-
idation approach [36].
Results
RTS,S/AS01E vaccine immunogenicity
Three doses of RTS,S/AS01E vaccination at 1-month in-
tervals induced a highly statistically significant increase in
antibody levels (log10MFI) to CSP FL, NANP repeat, and
C-term antigens and to HBsAg, from baseline (M0) to
1 month after the third dose (M3) for all Ig isotypes and
subclasses (p < 0.001) (Fig. 2). Comparisons of the magni-
tude of antibody responses to the RTS,S antigens between
the various isotypes/subclasses, and the correlations
among them, are shown in Additional file 1: Supplemen-
tary results Table S2. Fold changes in RTS,S-specific anti-
body levels at post-vaccination compared to baseline were
evaluated with mixed models (Additional file 1: Table S3).
Overall differences between pre- and post-vaccination con-
ferred by RTS,S were significant; for IgG, IgG1, and IgG3,
they were substantially higher than for IgG2 and IgG4;
changes for HBsAg were lesser than those for CSP. Com-
parator vaccinees had no or negligible increases in responses
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Fig. 2 RTS,S/AS01E vaccine immunogenicity: CSP and HBsAg antibody responses in RTS,S and comparator vaccinees comparing pre- and post-vaccination.
a IgG antibody levels (R = RTS,S; C = comparators). b IgM antibody levels. Groups were compared through t tests and p values adjusted by Holm for IgG
and IgM and by Benjamini-Hochberg for IgG1–4, as explained in the “Methods” section
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from pre- to post-vaccination. When contrasting RTS,S vs
comparators at post-vaccination, the highest ratios were
again recorded for IgG and IgG1 and the lowest for IgM,
followed by IgG4 and IgG2 (Additional file 1: Figure S4).
Effect of age
Children vaccinated with RTS,S/AS01E had significantly
higher levels of IgG to all CSP constructs, and of IgG1
and IgG3 (but not other isotypes/subclasses) to NANP
and C-term, than infants at M3 (Additional file 1: Figure
S5). Levels of antibodies to HBsAg at M3 were also
higher in RTS,S-vaccinated children than infants, except
for IgG2. Regarding changes in antibody levels from pre-
to post-vaccination, children had a greater increase to all
RTS,S antigens than infants, particularly for CSP FL (all
isotypes and subclasses) (Additional file 1: Table S3 and
Figure S6). Statistically significant or marginally signifi-
cant differences between infants and children were
recorded in IgG (CSP FL, C-term, and NANP), IgG1
(CSP FL), IgG2 (CSP FL and NANP), and IgG3 (CSP FL,
C-term, and NANP). For HBsAg, RTS,S-vaccinated chil-
dren had significantly higher pre- to post-vaccination
changes for IgG, IgM, and IgG1 than infants. Ratios of
antibody levels in RTS,S to comparators at post-vaccin-
ation in infants and children are reported in
Additional file 1: Figure S7. Using univariate linear
models adjusted by site, we evaluated whether Ig levels
induced by RTS,S vaccination changed with age when
computed as a continuous variable within infant and
children cohorts (Additional file 1: Table S4). We found
that for HBsAg (but not CSP), log10MFIs for most anti-
bodies significantly increased for every 1-week increase
in age at baseline in infants and children. Antibody sero-
positivity was consistent between age groups except for
HBsAg (Additional file 1: Table S5).
Effect of site
Levels of IgG, IgG1, and IgG3 to CSP or HBsAg in
RTS,S vaccinees at M3 were not different in the two
sites (Additional file 1: Figures S8 and S9 stratified also
by age), whereas levels of IgG2 to all CSP constructs and
IgG4 to CSP FL were significantly higher in Kintampo
(high MTI) than Manhiça (low MTI). Levels of anti-CSP
IgM at M3 did not differ by site, but anti-HBsAg IgMs
and IgG4 were higher in Manhiça than Kintampo (Add-
itional file 1: Table S6). Some associations between prior
clinical malaria episodes or between malaria transmission
season at M3 and antibody responses in univariate ana-
lysis were lost when adjusted by site (data not shown).
Effect of baseline CSP and HBsAg antibodies
Anti-CSP IgG levels at M0 were usually higher in infants
than children but not statistically significant with this lim-
ited sample size (Additional file 1: Figure S6). Significantly
higher IgM and lower IgG2 to HBsAg were detected in
children, who had been previously vaccinated with the
pentavalent DTwP-HBV-Hib vaccine (as part of the routine
expanded program of immunization (EPI)) compared to
infants (p < 0.001). Consistent with higher MTI, levels of
IgG, IgG1, IgG2, and IgG3 to CSP constructs (and of IgM
in children) were higher in Kintampo than Manhiça at
baseline, but this did not happen for antibodies against
HBsAg (Additional file 1: Table S7). In fact, pre-vaccination
levels of anti-HBsAg IgG2, and of IgG4 in children, were
significantly higher in Manhiça than in Kintampo.
We tested whether pre-vaccination levels had an impact
on post-RTS,S vaccination responses by fitting regression
models in each age group [18] and found no consistent
associations with anti-CSP antibodies. Correlation coeffi-
cients were low and with varying direction, although a
trend (p = 0.05) was observed for CSP NANP whereby
infants with higher M0 had lower M3 IgG and IgG1 levels
(Additional file 1: Figure S6, Fig. 3), but no effect was
detected in children, except for CSP FL IgG2. However,
there was a significant effect for HBsAg whereby children
with higher M0 IgG, IgM, and IgG2 (also for infants) had
higher M3 levels. There was no significant correlation be-
tween baseline HBsAg antibodies and CSP responses at
M3, or the opposite (data not shown).
Effect of baseline maternal P. falciparum antibodies
Summary scores based on IgGs to malarial antigens at
baseline in subjects younger than 10 months are shown
on Additional file 1: Table S8 and Figure S10. At M0, there
was a significant positive association between the maternal
malaria antibody index and anti-CSP IgGs, but this was
not the case for CSP IgM or for anti-HBsAg antibodies,
except IgG2 (Additional file 1: Table S9). In fact, there was
a significant negative association with anti-HBsAg IgM
(also in comparator vaccines at M3) and IgG3 levels at
baseline and a positive association for IgG2. Regarding the
impact on M3 RTS,S responses, maternal antibodies were
significantly negatively associated with IgG and IgG1
HBsAg levels (borderline associations to some CSP con-
structs) (Additional file 1: Table S9).
Effect of baseline P. falciparum exposure antibodies
Summary scores based on naturally acquired antimalar-
ial IgM (to distinguish from maternally derived IgG) are
shown in Additional file 1: Table S8 and Figure S10. At
M0, there was a significant positive association between
malaria exposure and IgMs to all CSPs and HBsAg
(Additional file 1: Table S10). When stratifying by age,
the association with HBsAg IgM was only significant in
infants (data not shown). Regarding the impact on M3
responses to RTS,S, the malaria exposure index was sig-
nificantly and positively associated with IgG, IgG1, and
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Fig. 3 Effect of pre-vaccination (M0) antibody levels on post-vaccination (M3) RTS,S immunogenicity. Some representative examples of antibody
isotypes/subclasses and antigens are shown. Spearman correlation coefficients are included as well as linear regression and non-parametric LOESS
estimations, as red and green lines, respectively. See Additional file 1: Figure S6 for further details
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IgM (borderline for IgG3) HBsAg levels, also in com-
parator vaccinees for IgM (Additional file 1: Table S10).
Multivariable linear regression analysis of immunogenicity
Factors significantly affecting the magnitude of RTS,S
antibody responses at M3 depending on the antigen/Ig
are shown in Table 1. Whilst all Ig tended to increase
with age, C-term and FL (but not NANP) CSP IgG2
levels decreased in subjects younger than 10 months
(Additional file 1: Table S11). Site strongly affected
HBsAg antibody levels, not only for IgM but also for
IgGs (Table 1), particularly in subjects of age < 10 months
(Additional file 1: Table S11), which were higher in Man-
hiça than Kintampo, as well as IgG2 and IgG4 to CSPs,
which were higher in Kintampo than Manhiça. Here,
prior malaria episodes (rather than exposure index) were
significantly associated with higher HBsAg IgG, IgG1,
and IgM, and CSP (NANP and C-term) IgG4, M3 levels.
Furthermore, a statistically significant negative impact of
high baseline NANP (borderline for C-term) CSP IgG
on M3 responses emerged, and the positive effect of
baseline HBsAg IgG2 and IgM remained. Higher anti-P.
falciparum maternal IgG at M0 was also inversely asso-
ciated with CSP (not HBsAg) IgG levels at M3 in sub-
jects age < 10-month old (Additional file 1: Table S11).
RTS,S/AS01E-induced antibody correlates of malaria disease
protection
Crude log10MFI levels of IgG, IgG1, and IgG3 to CSP con-
structs at M3 in RTS,S vaccinees were higher but not
significantly in those who did not present with clinical mal-
aria vs those who did over the 12-month follow-up period.
In contrast, levels of IgG2 to all CSP constructs and of
IgG4 to CSP FL were significantly lower in non-malaria
controls than in malaria cases (Additional file 1: Figures
S10–S13). A combined analysis of all IgG subclasses
showed that the ratio of cytophilic (IgG1 + IgG3) to
non-cytophilic (IgG2 + IgG4) antibodies to all CSP con-
structs was significantly higher among controls than cases
in RTS,S vaccinees but not in comparator vaccinees (Fig. 5).
Stratified by age, this difference occurred in children but
not in infants (Additional file 1: Figure S14). Stratified by
site, this was only seen for Kintampo but not for Manhiça
(Additional file 1: Figures S15 and S16).
Baseline levels of CSP IgG were generally higher in
subjects who developed clinical malaria than in those
who did not (Additional file 1: Table S12). An analysis of
the change in antibody responses between M0 and M3
in RTS,S vaccinees revealed significantly higher increase
of Ig CSP levels in those who were protected than in
those who subsequently suffered clinical malaria (Fig. 4).
Stratified by age, this difference was significant in chil-
dren but not in infants (Additional file 1: Figure S14).
Stratified by site, this was more apparent for Kintampo
than Manhiça (Additional file 1: Figure S15).
Regarding responses to the HBsAg component of the
RTS,S vaccine, levels of IgG, IgG1, IgG3, and IgM at M3
in RTS,S vaccinees but not in comparators were lower in
those who had clinical malaria over the 12-month
follow-up period vs those who did not (Additional file 1:
Figures S11–S13).
The covariates significantly associated with clinical mal-
aria risk in univariate logistic regression models (including
all vaccinees) were site, previous malaria episodes, WAZ,
HAZ, baseline CSP IgG (and IgG1), P. falciparum mater-
nal and exposure antibodies (Additional file 1: Tables
S13–S14). When adjusted by site (Kintampo had higher
odds of malaria than Manhiça), only age cohort and base-
line P. falciparum maternal and exposure antibodies were
statistically significant. Within RTS,S vaccinees, age cohort
and baseline P. falciparum maternal antibodies remained
significant. We next assessed if these covariates affected
the associations between CSP and HBsAg Ig responses
(M3 levels, M3-M0 changes, and M3 IgG subclass ratios)
and clinical malaria in RTS,S vaccines. In multivariable
regression models, the associations between antibody
responses and clinical malaria remained statistically sig-
nificant after correction for multiple comparisons for
anti-C-term CSP IgG2 levels, M3–M0 changes in IgG and
IgG1, and cytophilic to non-cytophilic IgG subclass ratio,
as well as anti-HBsAg levels (IgG, IgG1, IgG3) and sub-
class ratio (Table 2). In these models, age and site signifi-
cantly affected clinical malaria and, in some cases, also
baseline antibodies. Sex was not significantly associated
with clinical malaria, but there were some significant
interactions with antibody responses to RTS,S vaccination;
and antibodies appeared more strongly associated with
malaria disease protection in males rather than females
(data not shown). In addition, sex (p = 0.1) was retained in
all models including C-term CSP IgG2 responses (Table 2).
Machine learning multi-marker analyses (Fig. 5) revealed
a signature of protection against clinical malaria in RTS,S
vaccinees composed of antibodies to HBsAg (IgG3, IgG4,
IgM, and IgG1 at M3 and M0, and IgG2 at M0), to CSP
NANP (IgG3 at M3), and C-term (IgG1 and IgG at M3). In
analysis stratified by age and site, IgG3 NANP was more
prominent in infants in Manhiça, and IgG1 C-term in chil-
dren in Kintampo (Additional file 1: Table S14). Moreover, a
signature of malaria disease risk was also identified com-
posed of IgG2 responses to CSP C-term, NANP, and HBsAg
at M3; baseline responses to CSP C-term, NANP (IgG1,
IgG, IgG3, and IgM), and P. falciparum antigens (exposure
and maternal indices); and IgG4 responses to CSP NANP
and C-term at M3 (Fig. 5). In addition, IgG3 and IgM to
CSP C-term at M3 (in detriment of IgG1), and IgG1 and
IgM to CSP NANP at M3 (in detriment of IgG3), were also
associated with increased risk. In stratified analysis, M0
Ubillos et al. BMC Medicine          (2018) 16:197 Page 8 of 18
Ta
b
le
1
Fa
ct
or
s
af
fe
ct
in
g
th
e
im
m
un
og
en
ic
ity
of
RT
S,
S/
A
S0
1E
.M
ul
tiv
ar
ia
bl
e
lin
ea
r
m
od
el
s
in
cl
ud
in
g
RT
S,
S/
A
S0
1E
va
cc
in
ee
s
at
m
on
th
3
Is
ot
yp
e
A
nt
ig
en
A
ge
*
Si
te
Pr
io
r
ep
is
od
e†
Se
as
on
Ba
se
lin
e
Ig
Ex
po
su
re
in
de
x
Se
x
H
b
W
A
Z
H
A
Z
Ig
G
C
SP
FL
1.
21
(0
;2
.4
3)
,
0.
05
C
SP
C
-
te
rm
1.
1
(0
.0
1;
2.
2)
,
0.
04
8
99
.0
8
(−
16
.6
;3
75
.1
8)
,
0.
12
−
43
.9
9
(−
69
.7
2;
3.
61
),
0.
06
−
13
.8
(−
28
.2
;3
.5
),
0.
11
C
SP
N
A
N
P
1.
55
(0
.3
;2
.8
2)
,
0.
02
−
46
.1
5
(−
65
.9
9;
-1
4.
73
),
0.
00
9
−
14
.9
9
(−
30
.8
7;
4.
5)
,
0.
12
H
Bs
A
g
3.
97
(2
.8
3;
5.
12
),
<
0.
00
1
93
.1
4
(9
.1
8;
24
1.
67
),
0.
02
23
8.
29
(2
9.
17
;7
85
.9
5)
,
0.
01
−
18
.0
2
(−
32
.0
7;
−
1.
06
),
0.
04
Ig
G
1
C
SP
FL
−
21
.2
6
(−
41
.3
9;
5.
8)
,
0.
11
C
SP
C
-
te
rm
1.
54
(0
.1
7;
2.
94
),
0.
03
91
.1
7
(−
7.
67
;2
95
.8
2)
,
0.
08
16
6.
93
(−
18
.5
5;
77
4.
83
),
0.
1
−
21
.4
2
(−
42
.4
;7
.2
2)
,
0.
13
C
SP
N
A
N
P
−
44
.3
(−
63
.7
;-
14
.7
),
0.
08
8.
62
(0
.4
;1
7.
5)
,
0.
04
H
Bs
A
g
4.
28
(3
.0
9;
5.
49
),
<
0.
00
1
90
.6
1
(4
.9
;2
46
.3
5)
,
0.
03
16
1.
88
(−
4.
42
;6
17
.5
3)
,
0.
06
−
17
.5
2
(−
32
.3
;0
.4
3)
,0
.0
05
Ig
G
2
C
SP
FL
−
69
.3
(−
78
.8
6;
-5
5.
43
),
<
0.
00
1
3.
28
(−
7.
2;
0.
8)
,0
.1
1
C
SP
C
-
te
rm
−
74
.7
7
(−
84
.4
;-5
9.
2)
,
<
0.
00
1
C
SP
N
A
N
P
1.
2
(0
.2
5;
2.
16
),
0.
01
−
45
.4
5
(−
66
.6
6;
−
10
.7
2)
,
0.
02
30
.8
6
(−
8.
56
;8
7.
27
),
0.
14
−
5.
93
(−
10
.5
5;
-1
.0
7)
,
0.
02
25
.1
8
(−
6.
89
;6
8.
29
),
0.
14
−
24
.2
3
(−
37
.6
3;
−
7.
94
),
0.
00
6
H
Bs
A
g
2.
45
(1
.7
5;
3.
15
),
<
0.
00
1
31
8.
44
(2
34
.5
;4
23
),
<
0.
00
1
Ig
G
3
C
SP
FL
14
4.
38
(−
20
.2
9;
64
9.
19
),
0.
12
−
22
.6
3
(−
43
.2
;5
.3
1)
,
0.
1
C
SP
C
-
te
rm
1.
05
(−
0.
17
;2
.2
9)
,
0.
09
5.
84
(−
0.
92
;1
3.
06
),
0.
09
C
SP
N
A
N
P
1.
38
(−
0.
13
;2
.9
1)
,
0.
07
19
7.
82
(−
8.
62
;8
70
.6
7)
,
−
23
.0
8
(−
40
.1
4;
−
1.
15
),
Ubillos et al. BMC Medicine          (2018) 16:197 Page 9 of 18
Ta
b
le
1
Fa
ct
or
s
af
fe
ct
in
g
th
e
im
m
un
og
en
ic
ity
of
RT
S,
S/
A
S0
1E
.M
ul
tiv
ar
ia
bl
e
lin
ea
r
m
od
el
s
in
cl
ud
in
g
RT
S,
S/
A
S0
1E
va
cc
in
ee
s
at
m
on
th
3
(C
on
tin
ue
d)
Is
ot
yp
e
A
nt
ig
en
A
ge
*
Si
te
Pr
io
r
ep
is
od
e†
Se
as
on
Ba
se
lin
e
Ig
Ex
po
su
re
in
de
x
Se
x
H
b
W
A
Z
H
A
Z
0.
07
0.
04
1
H
Bs
A
g
1.
96
(1
.2
3;
2.
71
),
<
0.
00
1
20
.8
9
(3
.3
;4
1.
43
),
0.
00
2
Ig
G
4
C
SP
FL
−
52
.0
7
(−
75
.6
6;
−
5.
61
),
0.
03
12
3.
51
(−
21
.6
4;
53
7.
55
),
0.
13
8.
6
(1
.4
5;
16
.2
),
0.
02
−
22
.3
2
(−
40
.8
;2
.0
3)
,
0.
07
C
SP
C
-
te
rm
0.
93
(−
0.
38
;2
.2
5)
,0
.1
6
72
.9
3
(−
13
.5
6;
24
5.
99
),
0.
12
21
5.
08
(0
.4
9;
88
7.
87
),
0.
04
9
−
49
.5
9
(−
76
.3
4;
7.
39
),
0.
08
−
26
.5
2
(−
45
.3
9;
−
1.
14
),
0.
04
2
C
SP
N
A
N
P
30
4.
28
(7
2.
25
;8
48
.8
5)
,
0.
00
2
H
Bs
A
g
0.
57
(0
.3
3;
0.
82
),
<
0.
00
1
18
.4
9
(4
.3
9;
34
.4
9)
,
0.
00
9
19
.2
4
(−
2.
74
;4
6.
19
),
0.
09
55
.3
6
(−
6.
46
;1
58
.1
),
0.
09
−
4
(−
7.
75
;−
0.
1)
,0
.0
45
8.
14
(1
.4
2;
15
.3
),
0.
02
−
5.
15
(−
11
.0
5;
1.
14
),
0.
11
Ig
M
C
SP
FL
−
76
.8
2
(−
96
.2
3;
42
.5
1)
,
0.
11
−
14
.6
8
(−
27
.4
;0
.3
2)
,0
.0
55
C
SP
C
-
te
rm
62
.1
5
(6
.7
1;
14
6.
4)
,
0.
02
95
.0
3
(−
0.
67
;2
82
.9
4)
,0
.0
52
−
18
.5
2
(−
28
.3
;−
7.
4)
,0
.0
02
−
12
.6
4
(−
26
.4
;3
.7
3)
,
0.
12
C
SP
N
A
N
P
1.
07
(0
.0
5;
2.
09
),
0.
04
H
Bs
A
g
2.
17
(0
.8
7;
3.
48
),
0.
00
1
21
2.
61
(9
7.
4;
39
5.
11
),
<
0.
00
1
19
0.
2
(3
8.
4;
50
8.
6)
,
0.
00
5
12
0.
31
(4
9.
19
;2
25
),
<
0.
00
1
−
15
.8
6
(−
27
.0
3;
−
2.
99
),
0.
02
−
15
.5
3
(−
30
.0
1;
1.
95
),
0.
08
Th
e
co
ef
fic
ie
nt
s
in
di
ca
te
th
e
pe
rc
en
t
ch
an
ge
fo
r
a
un
it
ch
an
ge
in
th
e
pr
ed
ic
to
r
(9
5%
co
nf
id
en
ce
in
te
rv
al
s)
,t
he
p
va
lu
es
in
di
ca
te
d
ar
e
fo
r
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
co
va
ria
te
s
(in
ita
lic
s)
an
d
fo
r
th
os
e
th
at
im
pr
ov
ed
th
e
m
od
el
.M
al
ar
ia
tr
an
sm
is
si
on
se
as
on
at
m
on
th
3
sa
m
pl
e
co
lle
ct
io
n
(lo
w
vs
hi
gh
).
Ba
se
lin
e
an
tib
od
ie
s
to
th
e
sa
m
e
Ig
/a
nt
ig
en
.B
as
el
in
e
an
ti-
P.
fa
lc
ip
ar
um
ex
po
su
re
Ig
M
le
ve
ls
(e
xp
os
ur
e
PC
1
in
de
x)
.
Se
x
m
al
e
vs
fe
m
al
e,
H
b,
g/
dL
ba
se
lin
e
he
m
og
lo
bi
n,
W
A
Z
w
ei
gh
t-
fo
r-
ag
e
Z
sc
or
es
,H
A
Z
he
ig
ht
-f
or
-a
ge
Z
sc
or
es
*C
on
tin
uo
us
ag
e
at
w
ee
ks
.S
ite
(M
an
hi
ça
vs
Ki
nt
am
po
)
†M
al
ar
ia
ep
is
od
e
be
tw
ee
n
m
on
th
0
an
d
m
on
th
3
(y
es
vs
no
)
Ubillos et al. BMC Medicine          (2018) 16:197 Page 10 of 18
AB
Fig. 4 (See legend on next page.)
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IgG2 to CSP NANP and M0 IgG4 to CSP C-term were also
associated with risk in infants. These protective signatures
were not found in comparator vaccinees, in whom malaria
exposure index was the strongest risk variable.
Discussion
Our study confirms prior knowledge on RTS,S/AS01E im-
munogenicity and goes a significant step beyond in under-
standing its determinants and mode of action. The data
corroborate that vaccination induces a substantial increase
in anti-CSP and HBsAg IgG responses, higher in children
than in infants, which contributes to protection against
clinical malaria [18]. In addition, a set of novel findings ex-
pand the breadth of knowledge about RTS,S immunogen-
icity and potential correlates of protection.
First, we showed that antibodies to other CSP epitopes
in its C-terminal region are also elicited by RTS,S/
AS01E in African children (although seemingly at lower
levels compared to NANP repeat) and are the only ones
associated with clinical malaria protection in multivari-
able analysis in our study population. Inclusion of a CSP
FL construct allowed detecting responses of lower mag-
nitude possibly due to the additive response to multiple
B cell epitopes.
Second, we characterized Ig responses not previously
assessed, including IgM and IgG subclasses for all anti-
gens. We found that IgG1 predominates upon RTS,S
vaccination, followed by IgG3, with lower production of
IgG2 and IgG4. Furthermore, our data support that the
balance of anti-CSP IgG subclasses more than the total
IgG levels is important for protection against clinical
malaria, as a higher ratio of cytophilic IgG1 and IgG3 to
non-cytophilic IgG2 and IgG4 antibodies was associated
with antimalarial immunity. Thus, children who pre-
dominantly produced anti-CSP (particularly C-term)
IgG2 and IgG4 in detriment of IgG1 and IgG3 as a re-
sponse to vaccination were at higher risk of suffering
malaria disease. This is consistent with the notion that
acquired immunity is attributed to cytophilic rather than
non-cytophilic IgGs [37] due to their functional capacity
to fix complement and opsonize parasites for Fc binding
and phagocytosis [38, 39]; these mechanisms could also
be acting in CSP-mediated sporozoite immunity. Anti-
bodies to C-term CSP seem not important in blocking
hepatocyte invasion by sporozoites but could mediate
these other protective mechanisms. Recent studies have
shown that acquired human antibodies, and antibodies
to CSP, can fix and activate complement on the sporozoite
surface, leading to inhibition of motility [40]. This poten-
tial antibody-mediated mechanism of action of RTS,S
needs to be confirmed in future functional studies. Our
findings are, however, not in line with observations by
Chaudhury et al. [41], where IgG4 was associated with
protection against sporozoite challenge in RTS,S-vacci-
nated naïve adults and IgG4 inhibited phagocytosis medi-
ated by IgG1 and IgG3 when using the THP1
pro-monocytic cell line. That study also found that phago-
cytic activity using THP1 cells was not associated with
vaccine efficacy. It is possible that the mechanisms of im-
munity differ between vaccinated malaria-naive adults and
children resident in a malaria-endemic region. Further-
more, using THP-1 cells may not represent all Fc-receptor
interactions that occur with phagocytes in vivo due to dif-
ferences in Fc-receptor expression and function between
THP1 cells, monocytes, neutrophils, and other cells. Re-
cent studies have also highlighted differences in opsonic
phagocytosis activity when using purified monocytes ver-
sus whole-blood assays [42].
Third, we characterized the effect of baseline status,
including variables related to malaria exposure, on RTS,S
immunogenicity and efficacy. At the individual level, the
presence of antibodies at the time of vaccination due to
maternal transfer and/or to past/present infections or to
other vaccinations [43, 44] likely varies in infants and
children and may differentially affect RTS,S outcomes.
As expected, Kintampo had higher M0 levels of CSP
antibodies than Manhiça. The site did not seem to have
a major role in CSP antibody levels at M3, but because
of the different baselines, it had a significant effect on
change from M0 to M3 CSP responses. Thus, individuals
exposed to higher MTI had higher M0 Ig levels and
lower change in antibodies from M0 to M3. This was
manifested differently depending on age group: (i) higher
M0 IgG levels in infants than children presumably repre-
sented passively transferred maternal antibodies that, in
the absence of vaccination (comparators), decayed from
M0 to M3, and these were generally higher in Kintampo
than Manhiça due to higher malaria exposure in the
mothers; (ii) higher M0 IgG and IgM levels in children
represented those acquired upon infection and were also
higher in Kintampo than Manhiça. Season did not im-
pact the outcomes (consistent with a recent report [45])
as the majority of volunteers were vaccinated within re-
stricted time periods.
A prior analysis of the effect of baseline anti-NANP
CSP IgGs within the phase 3 trial [18] reported that
(See figure on previous page.)
Fig. 4 Association between CSP Ig responses after vaccination and RTS,S-induced protection. a Ratio of cytophilic IgG1 and IgG3 vs non-cytophilic
IgG2 and IgG4 antibodies, and increment of IgG levels between month 0 and month 3 in protected (NM = no clinical malaria) and non-protected
(M = clinical malaria). b Difference between month 3 and month 0 (M3–M0) cytophilic/non-cytophilic ratios. Groups were compared through t tests
and p values adjusted by Holm
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Fig. 5 Multi-marker correlates analyses by machine learning techniques. Results from three complementary methods are shown stratified by
vaccination group. a Elastic Net. b Support vector machines. c Random forest. d Schematic summary of the associations between the most
relevant antibody responses and clinical malaria in RTS,S vaccinees combining outputs from three machine learning methods
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pre-vaccination titers were associated with lower RTS,S
immunogenicity in infants and higher immunogenicity in
children. We also found a significant negative association
between anti-NANP CSP pre-vaccination levels and
post-vaccination IgG and IgG1 responses, particularly in
younger children. At baseline, anti-CSP IgGs in infants <
10 months correlated with IgG to P. falciparum antigens
used as markers of maternal antibodies, and anti-CSP
IgGs in children correlated with IgM to P. falciparum
antigens that are markers of current/recent exposure.
These maternal and exposure indices, obtained using an
unprecedented breadth of pre-erythrocytic and erythro-
cytic stage proteins, were significantly associated to some
CSP and HBsAg Ig responses at M3. Overall, the data
show that high concentrations of maternal CSP IgG at
baseline could interfere with RTS,S immunization by
binding the vaccine proteins and impeding antigen pres-
entation and subsequent response, resulting in lower im-
munogenicity in newborns.
More importantly, higher malaria exposure prior to
M0 positively predicted the occurrence of malaria cases
over the 12-month follow-up period after M3, while
lower levels of antibodies to CSP or P. falciparum anti-
gens at M0 predicted lower risk of clinical malaria dur-
ing the post-vaccination follow-up; this also applied for
comparator vaccinees at M3. Here, naturally acquired
CSP antibody levels also indicated malaria exposure. In
this line, it is well established that the strongest risk fac-
tor for future malaria disease is having had malaria epi-
sodes in the past [37]. In fact, malaria events prior to
M3 rendered participants more susceptible to future
malaria episodes, but this was largely explained by site,
with higher baseline MTI and malaria incidence in Kin-
tampo than Manhiça. As RTS,S vaccination induced a
potent increase in anti-CSP antibodies at M3, individuals
protected against clinical malaria had a significantly
higher increase in M0 to M3 Ig levels than the
non-protected, more remarkably for C-term Ig. The as-
sociations were significant mostly for Kintampo (where
the effect of malaria exposure was heavier) and children
(in whom there were little maternal antibodies and
RTS,S elicited higher M3 Ig levels). Thus, it appears that
RTS,S exerts a larger benefit (vaccine efficacy) when vac-
cinees have had less malaria exposure before M0, thus
that they are able to mount a higher (on average) CSP
IgG response at M3 upon vaccination, and this contrib-
utes more efficiently to controlling P. falciparum infec-
tion. This is in line with the results from the main
MAL055 trial with regard to the significant interaction
between vaccine efficacy and site in children (not in-
fants) whereby lower efficacy was generally estimated in
sites of higher MTI [14].
We and others have shown that malaria exposure alters
the phenotype and functional characteristics of memory B
lymphocytes [46, 47] and other cells, e.g., T helper [48],
that are responsible for antibody production. Individuals
under higher MTI may have an immune system that is
suppressed, de-regulated, or primed by natural exposure
to produce a different immune response that upon RTS,S
vaccination could deviate CSP response to predominantly
non-cytophilic antibodies and/or overall lower IgG levels.
Elicitation of IgE rather than IgG CSP responses [49] and
of TH2 rather than TH1 [23] may also be associated with
lower RTS,S efficacy. Induction of greater IgG1 and IgG3
relative to lower IgG2 and IgG4 in individuals under lower
MTI would lead to a better quality and more balanced im-
mune response associated with functional CSP
antibody-mediated vaccine protection. Our data strongly
support this assertion. Levels of IgG2 to all CSP constructs
and IgG4 to CSP FL (but not of IgG1 or IgG3) induced by
RTS,S vaccination were significantly higher with heavier
MTI. Other baseline variables not previously assessed in
RTS,S studies could influence the immune balance, and
particularly, the role of sex deserves more investigation
because of the increased overall mortality in girls than
boys found in a secondary analysis [50]. Baseline Hb,
WAZ, and HAZ were associated with antibody levels at
M3, suggesting that the health status of the child might
also affect the initial response to the vaccine, but this was
not significant after adjustment. Due to sample sizes, these
observations should be interpreted with caution but merit
further assessment. Thus, determinants of IgG2, IgG4, or
IgE CSP responses and exhausted TH and B cells associ-
ated with malaria infections need to be disentangled as
they appear relevant for vaccine success.
Remarkably, higher HBsAg antibody levels were asso-
ciated with less malaria disease risk in RTS,S vaccinees,
and this was consistent across Ig isotypes, ages, and sites
and confirmed in machine learning analysis. This un-
foreseen result could be an indirect association related
to a better general immune status in the volunteers pro-
tected against clinical malaria, who may respond more
potently to non-malarial antigen epitopes upon vaccin-
ation, or a surrogate of other protective mechanisms. Al-
ternatively, there may be a direct immunological
mediation whereby HBsAg-specific T cells might provide
help to B cells to produce CSP antibodies by virtue of
being presented together (hapten-carrier hypothesis).
The complex relationship between malaria exposure,
HBsAg antibodies, and clinical malaria risk will be the
subject of future investigations.
Our study design had some limitations that can be
mitigated in follow-up studies. In Kintampo, all children
who fulfilled the inclusion criteria, most of whom had
malaria, were analyzed. Whereas in Manhiça, a case-
control design was needed because there were fewer
cases; a cohort design would have required to increase
the number of samples substantially to have power to
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detect association with protection. In Manhiça, there
was also an age imbalance, as most cases were in infants.
Despite this and having many markers and multiple com-
parisons, the results were coherent and biologically plaus-
ible. Thus, the impacts of CSP IgG subclasses, baseline
malaria exposure, and of HBsAg Ig levels, on clinical mal-
aria risk, were consistent.
Conclusions
Our characterization of an expanded breadth of antigen
epitopes and Ig isotypes/subclasses induced by RTS,S, in-
cluding non-CSP P. falciparum antigens as markers of
maternal antibodies and malaria exposure, led to a better
understanding of baseline determinants of vaccine take
and protection against clinical malaria. We identified new
potential correlates of malaria disease risk and protection,
including IgG subclasses, baseline antibody levels, and
HBsAg antibodies. These data shed new light into the
mode of action of RTS,S, further evidencing that it is more
complex and multifactorial than previously thought. Fu-
ture studies should assess the function of the antibodies,
their correlation with cellular immune responses associ-
ated with clinical malaria protection and risk, and the kin-
etics of peak and post-booster CSP and HBsAg responses
over time. Elucidating mechanisms of RTS,S immunity
and correlates will be translated into a more rational de-
velopment, testing, and deployment of next-generation
vaccines. Protective responses identified could be favored
with appropriate adjuvants, delivery systems, and/or vac-
cination schedules, including combination with antimalar-
ial drugs.
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